End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
82.7 EUR | -5.27% | -5.27% | -13.39% |
06-18 | US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial | MT |
06-17 | Sector Update: Health Care Stocks Ease in Afternoon Trading | MT |
Sales 2024 * | 2.75B 2.93B 232B | Sales 2025 * | 2.74B 2.93B 232B | Capitalization | 19.12B 20.44B 1,617B |
---|---|---|---|---|---|
Net income 2024 * | -419M -448M -35.44B | Net income 2025 * | -548M -586M -46.35B | EV / Sales 2024 * | 2.35 x |
Net cash position 2024 * | 12.67B 13.55B 1,072B | Net cash position 2025 * | 12.02B 12.85B 1,017B | EV / Sales 2025 * | 2.59 x |
P/E ratio 2024 * |
-43.8
x | P/E ratio 2025 * |
-34.7
x | Employees | 6,133 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
Latest transcript on BioNTech SE
1 day | -5.27% | ||
1 week | -5.27% | ||
Current month | -10.16% | ||
1 month | -1.78% | ||
3 months | -3.25% | ||
6 months | -12.62% | ||
Current year | -13.39% |
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 01/06/08 |
Özlem Türeci
FOU | Founder | 57 | 01/06/08 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 31/12/21 |
Director/Board Member | 67 | 01/06/08 | |
Helmut Jeggle
CHM | Chairman | 53 | 01/06/08 |
Date | Price | Change | Volume |
---|---|---|---|
21/06/24 | 78.75 | -2.11% | 0 |
20/06/24 | 80.45 | +0.31% | 0 |
19/06/24 | 80.2 | -1.35% | 4 |
18/06/24 | 81.3 | -1.69% | 0 |
17/06/24 | 82.7 | -5.27% | 10 |
End-of-day quote Wiener Boerse, June 16, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- BNTX Stock
- BNTX Stock